Clinical Trial

Early Discontinuation of Antibiotic Therapy in Elderly Patients Hospitalized for a Viral Infection

Study acronym: ABUSIV
Recruiting
View on ClinicalTrials.gov →
Summary
Among winter respiratory viruses, influenza is the most common and therefore responsible for the highest mortality, but parainfluenza and RSV viruses have an even higher risk of mortality (1.6 to 1.9 times), this toll being paid mainly by the elderly and co-morbid population. Futhermore, SARS-Cov2 will probably become endemic and/or epidemic with the same targets of fragile patients. These viral infections are serious, however a bacterial co-infection worsens the prognosis even more: excess risk of mortality = 2.6, 95% CI \[1.9-3.7\]. Although rare, these co-infections are the subject of a prescription of antibiotics in more than 50% of influenza infections or other serious viral infections. Mainly due to this excess risk of mortality associated with the difficulty of diagnosing these co-infections. Proper antibiotic use requires preventing this misuse and its harmful consequences in the short and long term at all costs. It is therefore imperative to have solid (grade A) evidence showing that antibiotic therapy in viral infections is not only futile but also potentially harmful.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-12; most recent amendment 2026-01-15.
Status change: Not Yet Recruiting → Recruiting 2026-01-15
Trial Details
NCT Number NCT07030673
Lead Sponsor Centre Hospitalier Universitaire, Amiens
Collaborators: University Hospital, Rouen, Centre Hospitalier de Beauvais, University Hospital, Caen, Hôpital Les Bateliers, CHU de Lille, Centre Hospitalier Roubaix, CH SOISSONS, Tourcoing Hospital
Conditions Elderly, Antibiotics Overuse, Viral Infections, PCR Multiplex
Enrollment 256 participants
Start Date 2025-02-14
Primary Completion 2027-03 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-01-16